{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:10:24Z","timestamp":1779171024154,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cardiac involvement (CI) is a major determinant of poor prognosis in idiopathic inflammatory myopathies (IIM). Soluble suppression of tumorigenicity 2 (sST2) is a biomarker linked to cardiac inflammation and remodelling, but its role has scarcely been explored in IIM. We aimed to investigate the levels of sST2 and its longitudinal profile in patients with IIM and CI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum sST2 levels were measured longitudinally over the course of two years in 34 patients with newly diagnosed IIM and in 109 patients with established IIM from a cross-sectional cohort, as well as in age and gender matched healthy controls (HC) and in patients with rheumatoid arthritis (RA). CI was assessed using cardiac magnetic resonance (CMR) in newly diagnosed IIM patients. Associations between sST2 and clinical parameters were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with newly diagnosed IIM exhibited significantly higher sST2 levels at diagnosis compared to HC (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and patients with established IIM (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). sST2 levels were highest at diagnosis, decreased significantly by 6\u00a0months, and remained lower during follow-up. sST2 levels were positively associated with cardiac troponin I and N-terminal pro-brain natriuretic peptide (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001 and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0001, respectively). Importantly, IIM patients with active CMR-verified CI exhibited significantly higher sST2 levels than those without ongoing CI. In contrast, patients with established IIM had sST2 levels comparable to HC and RA patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sST2 is elevated in early IIM and closely associated with cardiac biomarkers and CMR-verified cardiac inflammation. Its dynamic decline with treatment suggests potential utility as a biomarker for early detection and monitoring of CI in IIM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-026-03830-w","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:26:54Z","timestamp":1779164814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated sST2 associates with cardiac involvement and declines after treatment in newly diagnosed patients with idiopathic inflammatory myopathies"],"prefix":"10.1186","volume":"28","author":[{"given":"Balsam","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna-Karin H.","family":"Ekwall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Glinatsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egidija","family":"Sakiniene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhicheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rille","family":"Pullerits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"1","key":"3830_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"3830_CR2","first-page":"213","volume":"42","author":"E Conticini","year":"2024","unstructured":"Conticini E, Dourado E, Bottazzi F, Cardelli C, Bruno L, Schmidt J, et al. Idiopathic inflammatory myopathies: one year in review 2023. Clin Exp Rheumatol. 2024;42(2):213\u201324.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 4","key":"3830_CR3","doi-asserted-by":"publisher","first-page":"iv18","DOI":"10.1093\/rheumatology\/kel311","volume":"45","author":"IE Lundberg","year":"2006","unstructured":"Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford). 2006;45(Suppl 4):iv18-21.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3830_CR4","first-page":"309","volume":"42","author":"A Gil-Vila","year":"2024","unstructured":"Gil-Vila A, Burcet-Rodriguez G, Trallero-Aragu\u00e1s E, Cuellar-Calabria H, Selva-O\u2019Callaghan A. Subclinical myocardial involvement in a cohort of patients with antisynthetase syndrome. Clin Exp Rheumatol. 2024;42(2):309\u201315.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"3830_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1532-429X-16-14","volume":"16","author":"J Schumm","year":"2014","unstructured":"Schumm J, Greulich S, Wagner A, Gr\u00fcn S, Ong P, Bentz K, et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson. 2014;16(1):14.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"3830_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/art.41907","volume":"74","author":"CY Lin","year":"2022","unstructured":"Lin CY, Chen HA, Hsu TC, Wu CH, Su YJ, Hsu CY. Time-dependent analysis of risk of new-onset heart failure among patients with polymyositis and dermatomyositis. Arthritis Rheumatol. 2022;74(1):140\u20139.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3830_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/01.md.0000109755.65914.5e","volume":"83","author":"K Dank\u00f3","year":"2004","unstructured":"Dank\u00f3 K, Ponyi A, Constantin T, Borgulya G, Szegedi G. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore). 2004;83(1):35\u201342.","journal-title":"Medicine (Baltimore)"},{"issue":"23","key":"3830_CR8","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","volume":"106","author":"EO Weinberg","year":"2002","unstructured":"Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961\u20136.","journal-title":"Circulation"},{"issue":"5","key":"3830_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","volume":"107","author":"EO Weinberg","year":"2003","unstructured":"Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107(5):721\u20136.","journal-title":"Circulation"},{"key":"3830_CR10","doi-asserted-by":"publisher","first-page":"105619","DOI":"10.1016\/j.biocel.2019.105619","volume":"116","author":"E Vianello","year":"2019","unstructured":"Vianello E, Dozio E, Tacchini L, Frati L, CorsiRomanelli MM. ST2\/IL-33 signaling in cardiac fibrosis. Int J Biochem Cell Biol. 2019;116:105619.","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"3830_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1161\/CIRCHEARTFAILURE.109.873240","volume":"2","author":"K Seki","year":"2009","unstructured":"Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2(6):684\u201391.","journal-title":"Circ Heart Fail"},{"issue":"7 Suppl","key":"3830_CR12","doi-asserted-by":"publisher","first-page":"3b","DOI":"10.1016\/j.amjcard.2015.01.034","volume":"115","author":"DA Pascual-Figal","year":"2015","unstructured":"Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015;115(7 Suppl):3b\u20137b.","journal-title":"Am J Cardiol"},{"issue":"1","key":"3830_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.hfc.2017.08.005","volume":"14","author":"CP McCarthy","year":"2018","unstructured":"McCarthy CP, Januzzi JL Jr. Soluble ST2 in Heart Failure. Heart Fail Clin. 2018;14(1):41\u20138.","journal-title":"Heart Fail Clin"},{"issue":"17","key":"3830_CR14","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","volume":"74","author":"A Aimo","year":"2019","unstructured":"Aimo A, Januzzi JL Jr, Bayes-Genis A, Vergaro G, Sciarrone P, Passino C, et al. Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week. J Am Coll Cardiol. 2019;74(17):2193\u2013203.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"3830_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479\u201390.","journal-title":"Immunity"},{"key":"3830_CR16","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.3389\/fimmu.2018.02432","volume":"9","author":"OS Kotsiou","year":"2018","unstructured":"Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33\/ST2 axis in organ fibrosis. Front Immunol. 2018;9:2432.","journal-title":"Front Immunol"},{"issue":"2","key":"3830_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1432-1327.1999.00615.x","volume":"264","author":"H Iwahana","year":"1999","unstructured":"Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem. 1999;264(2):397\u2013406.","journal-title":"Eur J Biochem"},{"key":"3830_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.semcdb.2016.08.007","volume":"61","author":"NL Millar","year":"2017","unstructured":"Millar NL, O\u2019Donnell C, McInnes IB, Brint E. Wounds that heal and wounds that don\u2019t - the role of the IL-33\/ST2 pathway in tissue repair and tumorigenesis. Semin Cell Dev Biol. 2017;61:41\u201350.","journal-title":"Semin Cell Dev Biol"},{"issue":"6","key":"3830_CR19","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","volume":"117","author":"S Sanada","year":"2007","unstructured":"Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117(6):1538\u201349.","journal-title":"J Clin Invest"},{"key":"3830_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead182","author":"J Sun","year":"2023","unstructured":"Sun J, Xu Y, Wu Y, Sun J, Yin G, Chen Y, et al. The diagnostic value of sST2 for myocardial fibrosis in idiopathic inflammatory myopathies in subclinical stage of cardiac involvement. Rheumatology (Oxford). 2023. https:\/\/doi.org\/10.1093\/rheumatology\/kead182.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"3830_CR21","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3830_CR22","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest. 2010;138(6):1464\u201374.","journal-title":"Chest"},{"issue":"4","key":"3830_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","volume":"84","author":"Y Troyanov","year":"2005","unstructured":"Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Sen\u00e9cal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients. Medicine (Baltimore). 2005;84(4):231\u201349.","journal-title":"Medicine (Baltimore)"},{"key":"3830_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020399","author":"CL Polte","year":"2022","unstructured":"Polte CL, Bobbio E, Bollano E, Bergh N, Polte C, Himmelman J, et al. Cardiovascular magnetic resonance in myocarditis. Diagnostics. 2022. https:\/\/doi.org\/10.3390\/diagnostics12020399.","journal-title":"Diagnostics"},{"issue":"24","key":"3830_CR25","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: Expert recommendations. J Am Coll Cardiol. 2018;72(24):3158\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3830_CR26","first-page":"320","volume":"44","author":"B Hanna","year":"2026","unstructured":"Hanna B, Polte CL, Sakiniene E, von Br\u00f6msen J, Bollano E, Lundberg IE, et al. Cardiac involvement in newly diagnosed patients with idiopathic inflammatory myopathies is associated with skeletal muscle involvement. Clin Exp Rheumatol. 2026;44(2):320\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"3830_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"3830_CR28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403\u20137.","journal-title":"N Engl J Med"},{"key":"3830_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2025.2470011","author":"B Hanna","year":"2025","unstructured":"Hanna B, Polte CL, Sakiniene E, von Br\u00f6msen J, Bollano E, Pullerits R, et al. Cardiovascular risk and cardiac involvement in idiopathic inflammatory myopathies: Insights from a cross-sectional Swedish single-centre study. Scand J Rheumatol. 2025. https:\/\/doi.org\/10.1080\/03009742.2025.2470011.","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"3830_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","volume":"14","author":"LG Rider","year":"2018","unstructured":"Rider LG, Aggarwal R, Machado PM, Hogrel JY, Reed AM, Christopher-Stine L, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14(5):303\u201318.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"3830_CR31","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","volume":"40","author":"FW Miller","year":"2001","unstructured":"Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40(11):1262\u201373.","journal-title":"Rheumatology (Oxford)"},{"key":"3830_CR32","doi-asserted-by":"publisher","first-page":"1073814","DOI":"10.3389\/fcvm.2022.1073814","volume":"9","author":"DJ Beetler","year":"2022","unstructured":"Beetler DJ, Bruno KA, Di Florio DN, Douglass EJ, Shrestha S, Tsch\u00f6pe C, et al. Sex and age differences in sST2 in cardiovascular disease. Front Cardiovasc Med. 2022;9:1073814.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3830_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jbspin.2011.02.011","volume":"79","author":"D Talabot-Ayer","year":"2012","unstructured":"Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine. 2012;79(1):32\u20137.","journal-title":"Joint Bone Spine"},{"issue":"2","key":"3830_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3899\/jrheum.140234","volume":"42","author":"SM Jung","year":"2015","unstructured":"Jung SM, Lee J, Baek SY, Lee JH, Lee J, Park KS, et al. The interleukin 33\/ST2 axis in patients with primary Sjogren syndrome: Expression in serum and salivary glands, and the clinical association. J Rheumatol. 2015;42(2):264\u201371.","journal-title":"J Rheumatol"},{"issue":"3","key":"3830_CR35","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/rheumatology\/kep402","volume":"49","author":"MY Mok","year":"2010","unstructured":"Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan EY, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2010;49(3):520\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"3830_CR36","first-page":"1295","volume":"20","author":"DP Margiotta","year":"2016","unstructured":"Margiotta DP, Navarini L, Vadacca M, Lo Vullo M, Pignataro F, Basta F, et al. The IL33\/ST2 axis in Sjogren syndrome in relation to disease activity. Eur Rev Med Pharmacol Sci. 2016;20(7):1295\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3830_CR37","doi-asserted-by":"publisher","first-page":"117609","DOI":"10.1016\/j.cca.2023.117609","volume":"551","author":"Z Ye","year":"2023","unstructured":"Ye Z, Zhang T, Xu M, Xu J. Association of soluble ST2 with disease activity in pediatric systemic lupus erythematosus. Clin Chim Acta. 2023;551:117609.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"3830_CR38","first-page":"897","volume":"40","author":"A Moreau","year":"2022","unstructured":"Moreau A, Nicaise C, Awada A, Soyfoo MS. Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis. Clin Exp Rheumatol. 2022;40(5):897\u2013903.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"3830_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/ncpcardio0158","volume":"2","author":"J Diez","year":"2005","unstructured":"Diez J, Gonzalez A, Lopez B, Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med. 2005;2(4):209\u201316.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"3830_CR40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev.physiol.59.1.551","volume":"59","author":"J Sadoshima","year":"1997","unstructured":"Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol. 1997;59:551\u201371.","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"3830_CR41","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1084\/jem.20071868","volume":"205","author":"AM Miller","year":"2008","unstructured":"Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL-33 reduces the development of atherosclerosis. J Exp Med. 2008;205(2):339\u201346.","journal-title":"J Exp Med"},{"issue":"2","key":"3830_CR42","doi-asserted-by":"publisher","first-page":"e008968","DOI":"10.1161\/JAHA.118.008968","volume":"8","author":"MJ Coronado","year":"2019","unstructured":"Coronado MJ, Bruno KA, Blauwet LA, Tschope C, Cunningham MW, Pankuweit S, et al. Elevated Sera sST2 Is associated with heart failure in Men <\/=50 Years Old With Myocarditis. J Am Heart Assoc. 2019;8(2):e008968.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"3830_CR43","doi-asserted-by":"publisher","first-page":"e024417","DOI":"10.1161\/JAHA.121.024417","volume":"11","author":"J Wang","year":"2022","unstructured":"Wang J, He M, Li H, Chen Y, Nie X, Cai Y, et al. Soluble ST2 is a sensitive and specific biomarker for fulminant myocarditis. J Am Heart Assoc. 2022;11(7):e024417.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"3830_CR44","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCRESAHA.110.218867","volume":"107","author":"AM Miller","year":"2010","unstructured":"Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107(5):650\u20138.","journal-title":"Circ Res"},{"issue":"6","key":"3830_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3343\/alm.2016.36.6.542","volume":"36","author":"V Celic","year":"2016","unstructured":"Celic V, Majstorovic A, Pencic-Popovic B, Sljivic A, Lopez-Andres N, Roy I, et al. Soluble ST2 levels and left ventricular structure and function in patients with metabolic syndrome. Ann Lab Med. 2016;36(6):542\u20139.","journal-title":"Ann Lab Med"},{"key":"3830_CR46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diabres.2016.06.006","volume":"118","author":"YH Lin","year":"2016","unstructured":"Lin YH, Zhang RC, Hou LB, Wang KJ, Ye ZN, Huang T, et al. Distribution and clinical association of plasma soluble ST2 during the development of type 2 diabetes. Diabetes Res Clin Pract. 2016;118:140\u20135.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"3830_CR47","doi-asserted-by":"publisher","first-page":"e47830","DOI":"10.1371\/journal.pone.0047830","volume":"7","author":"AM Miller","year":"2012","unstructured":"Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, Burns H, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS ONE. 2012;7(10):e47830.","journal-title":"PLoS ONE"},{"issue":"12","key":"3830_CR48","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1373\/clinchem.2012.192153","volume":"58","author":"EE Coglianese","year":"2012","unstructured":"Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012;58(12):1673\u201381.","journal-title":"Clin Chem"},{"issue":"4","key":"3830_CR49","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/rheumatology\/kead182","volume":"63","author":"J Sun","year":"2024","unstructured":"Sun J, Xu Y, Wu Y, Sun J, Yin G, Chen Y, et al. The diagnostic value of sST2 for myocardial fibrosis in idiopathic inflammatory myopathies in subclinical stage of cardiac involvement. Rheumatology (Oxford). 2024;63(4):1172\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"3830_CR50","first-page":"428","volume":"31","author":"L Yuan","year":"2013","unstructured":"Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol. 2013;31(3):428\u201332.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03830-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03830-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03830-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:02:21Z","timestamp":1779170541000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03830-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3830"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03830-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was collected, and the study was approved by the Ethics Review Authority of Sweden (Dnr. 2019\u201304253).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"109"}}